Kesi S Michael (Kesi Michael)

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 3

Top Topics

Smoking Cessation

Genetic Diversity

Small Cell Lung Cancer

Top Venues

JCO precision oncology

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Michael L Cheng, Marina S D Milan, Rubii M Tamen, Arrien A Bertram, Kesi S Michael, Biagio Ricciuti, Kenneth L Kehl, Mark M Awad, Lynette M Sholl, Cloud P Paweletz, Pasi A Jänne
Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC. JCO precision oncology 5 (2022)
Michael L Cheng, Jessica K Lee, Rachit Kumar, Harry Klein, Kira Raskina, Alexa B Schrock, Kesi S Michael, Tali Mazor, Ethan Cerami, Geoffrey R Oxnard, David R Liu, Himisha Beltran, Lynette M Sholl, Mizuki Nishino, Pasi A Janne
Response to MEK Inhibitor Therapy in MAP2K1 ( MEK1 ) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer. JCO precision oncology 6 (2022)
Pınar Özden Eser, Raymond M Paranal, Jieun Son, Elena Ivanova, Yanan Kuang, Heidi M Haikala, Ciric To, Jeffrey J Okoro, Kshiti H Dholakia, Jihyun Choi, Yoonji Eum, Atsuko Ogino, Pavlos Missios, Dalia Ercan, Man Xu, Michael J Poitras, Stephen Wang, Kenneth H Ngo, Michael Dills, Masahiko Yanagita, Timothy Lopez, Mika Lin, Jeanelle Tsai, Nicolas Floch, Emily S Chambers, Jennifer Heng, Rana Anjum, Alison D Santucci, Kesi S Michael, Alwin G Schuller, Darren Ae Cross, Paul D Smith, Geoffrey R Oxnard, David A Barbie, Lynette M Sholl, Magda Bahcall, Sangeetha Palakurthi, Prafulla C Gokhale, Cloud P Paweletz, George Q Daley, Pasi A Janne
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer. Science translational medicine 13 (609) (2021)